Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia (NCT05928390)
A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
🩺 Plain-English Summary (8th-Grade Level)
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Who can join: Review the eligibility criteria below.
Location: Stanford University School of Medicine, Endocrinology, 800 Welch Road, — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- Stanford University School of Medicine, Endocrinology, 800 Welch Road, — Palo Alto, California
- Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- NOLA Care — Metairie, Louisiana
- Velocity Clinical Research - Annapolis — Annapolis, Maryland
- Joslin Diabetes CenterJoslin Diabetes Center, One Joslin Place — Boston, Massachusetts
- Mayo Clinic - Rochester, 200 First Street, SW, 55905 — Rochester, Minnesota
- Montefiore Medical Center, 111 E 210th Street, — The Bronx, New York
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, — San Antonio, Texas
- University of Wisconsin Health W. E. Clinic END, 451 Junction Rd, — Madison, Wisconsin
- Universitaire Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology,Herestraat 49 — Leuven,
- AP-HP Hopital Europeen Georges Pompidou, 20, rue Leblanc, — Paris,
- HCL Centre Hospitalier Lyon Sud — Pierre-Bénite,
- Hopital Rangueil, Attachée de Recherche Clinique, Centre Investigation Clinique, CHU, Cedex 9, France — Toulouse,
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola — Bologna,
- Azienda Ospedale - Università Padova, Clinica Medica 3, Via Giustiniani, 2, — Padova,
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone — Palermo,
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, L.go Gemelli 8 — Rome,
- Hospital Universitario Vall d'Hebron, Passeig Vall d´Hebron 119-129, Spain — Barcelona,
- Hospital Clinic Barcelona, Lipid Clinic End, Nutr. Service Hospital Clinic, C. Villarroel, 170, — Barcelona,
- Hospital Germans Trias i Pujol — Barcelona,
- Hospital Universitario Reina Sofia — Córdoba,
- Hospital Universitari de Girona Dr. Josep Trueta — Girona,
- Hospital Clinico San Carlos, C/ Prof Martin Lagos s/n, Spain — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Post-Bariatric Hypoglycemia
- Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia — Stanford, California
Explore by condition: All Post-Bariatric Hypoglycemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.